IP Library Granted Patent US 8,076,135
Granted Patent B2
US 8,076,135 · App. 12/173,330 · Granted Dec 13, 2011

Method of preparing a treatment effective amount of allogeneic T-cells

Assignee: Immunovative Therapies Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,135
App. No.
12/173,330
Granted
Dec 13, 2011
Kind
B2
Abstract

Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable nanospheres or microspheres coated with a material capable of cross-linking the agents attached to the T-cell surface moieties. Alternatively, the formulation may be made by mixing a population of T-cells with biodegradable nanospheres or microspheres coated with a first material and one or more second materials. The first material binds the second material and the second material has reactivity for surface moieties on the T-cells and the interaction of the second materials with the T-cells causes the activation of the T-cells. In either method, the mixture of T-cells and biodegradable spheres are suspended in a medium suitable for infusion, and the mixture is packaged in a container.

Claims (19)

1. A method for preparing a treatment effective amount of cells for infusion, of which a portion are allogeneic T-cells, the method comprising:

labeling the allogeneic T-cells with one or more agents which have reactivity for T-cell surface moieties capable of delivering activation signals upon cross-linking;

suspending the mixture of labeled allogeneic T-cells in an activated state with a cross-linking agent in a medium suitable for infusion;

packaging the mixture in a suitable container; and

administering the mixture to a patient allogeneically.

2. The method of claim 1 wherein the mixture is administered, applied, self-administered or self-applied subcutaneously, intramuscularly, intradermally, intravenously or intra-arterially.

3. The method of claim 1 wherein the container is a syringe or an IV infusion bag.

4. The method of claim 1 wherein the container is collapsible.

5. The method of claim 4 wherein the container includes opposing walls of flexible material and an exit tube.

6. A method for preparing a treatment effective amount of cells for infusion, of which a portion are allogeneic T-cells, the method comprising:

mixing a population of allogeneic T-cells with a first material and one or more second materials;

whereas the first material cross-links the second materials, and the second materials have reactivity for surface moieties on the T-cells, and whereas the interaction of the second materials with the T-cells causes the activation of the T-cells;

suspending the mixture of allogeneic T-cells in an activated state with a cross-linking agent in a medium suitable for infusion;

packaging the mixture in a container; and

administering parenterally the mixture to a patient allogeneically.

7. The method of claim 6 wherein the container is a syringe or an IV infusion bag.

8. The method of claim 6 wherein the container is collapsible.

9. The method of claim 8 wherein the container includes opposing walls of flexible material and an exit tube.

10. The method of claim 6 wherein the package mixture of the T-cell concentration of at least 1×10 7 cells per ml of infusion media.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OS THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 050489 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 28, 2020
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 052915/0513 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME FROM IMMUNOVATIVE THERAPIES, LTD. TO MICHAEL HAR-NOY ON THE ORIGINAL COVER SHEET PREVIOUSLY RECORDED ON REEL 050489 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 2, 2019
From: HAR-NOY, MICHAEL
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050610/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: IMMUNOVATIVE THERAPIES, LTD.
To: MIRROR BIOLOGICS, INC.
Reel/Frame 050489/0245 →
RESCISSION Recorded Sep 12, 2019
From: HAR-NOY, MICHAEL
To: HAR-NOY, MICHAEL
Reel/Frame 050467/0081 →
Continuity (7)
Division 11069010 · Mar 1, 2005
Continuation In Part 10838454 · May 4, 2004
Provisional Application 60470171 · May 13, 2003
Provisional Application 60545450 · Feb 18, 2004
Provisional Application 60547966 · Feb 26, 2004
Provisional Application 60549032 · Mar 1, 2004
Related Publication 20080279836A1 · Nov 13, 2008